Eli M Roth

Summary

Publications

  1. doi request reprint Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies
    Eli M Roth
    Sterling Research Group, Cincinnati, OH 45219, USA
    J Clin Lipidol 6:534-44. 2012
  2. doi request reprint Fish oil for primary and secondary prevention of coronary heart disease
    Eli M Roth
    Division of Cardiovascular Diseases, University of Cincinnati College of Medicine and Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Curr Atheroscler Rep 12:66-72. 2010
  3. doi request reprint Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
    Eli M Roth
    Sterling Research Group, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:175-86. 2010
  4. doi request reprint Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study
    Eli M Roth
    Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Cardiovasc Drugs Ther 24:421-8. 2010
  5. doi request reprint Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
    Eli M Roth
    Sterling Research Group, University of Cincinnati, Cincinnati, Ohio, USA
    J Cardiovasc Pharmacol 54:196-203. 2009
  6. doi request reprint Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    Eli M Roth
    Sterling Research Group, Cincinnati, OH, USA
    N Engl J Med 367:1891-900. 2012
  7. pmc Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Eur Heart J 31:480-8. 2010

Detail Information

Publications7

  1. doi request reprint Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies
    Eli M Roth
    Sterling Research Group, Cincinnati, OH 45219, USA
    J Clin Lipidol 6:534-44. 2012
    ..These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels...
  2. doi request reprint Fish oil for primary and secondary prevention of coronary heart disease
    Eli M Roth
    Division of Cardiovascular Diseases, University of Cincinnati College of Medicine and Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Curr Atheroscler Rep 12:66-72. 2010
    ..These data have led to specific recommendations for use of omega-3 fatty acids in several cardiovascular areas...
  3. doi request reprint Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
    Eli M Roth
    Sterling Research Group, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:175-86. 2010
    ....
  4. doi request reprint Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study
    Eli M Roth
    Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Cardiovasc Drugs Ther 24:421-8. 2010
    ..This phase 3, multicenter, randomized, double-blind study evaluated the efficacy and safety of rosuvastatin 5 mg coadministered with fenofibric acid 135 mg in patients with mixed dyslipidemia...
  5. doi request reprint Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
    Eli M Roth
    Sterling Research Group, University of Cincinnati, Cincinnati, Ohio, USA
    J Cardiovasc Pharmacol 54:196-203. 2009
    ..Given that some patients may not achieve optimal TG levels with a single agent, we hypothesized that concomitant use of P-OM3 or addition of P-OM3 to FENO would result in a TG reduction greater than that with FENO alone...
  6. doi request reprint Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    Eli M Roth
    Sterling Research Group, Cincinnati, OH, USA
    N Engl J Med 367:1891-900. 2012
    ..REGN727/SAR236553 (designated here as SAR236553), a fully human PCSK9 monoclonal antibody, increases the recycling of LDL receptors and reduces LDL cholesterol levels...
  7. pmc Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Eur Heart J 31:480-8. 2010
    ....